Antimicrobial drugs applied topically offer several advantages. However, the widespread use of antibiotics has led to increasing antimicrobial resistance. One interesting approach in the drug discovery process is drug repurposing. Disulfiram, which was originally approved as an anti-alcoholism drug, offers an attractive alternative to treat topical multidrug resistance bacteria in skin human infections. This study aimed to evaluate the biopharmaceutical characteristics of the drug and the effects arising from its topical application in detail. Microdilution susceptibility testing showed antibacterial activity against Gram-positive bacteria and . Dermal absorption revealed no permeation in pig skin. The quantification of the drug retained in pig skin demonstrated concentrations in the stratum corneum and epidermis, enough to treat skin infections. Moreover, in vitro cytotoxicity and micro-array analyses were performed to better understand the mechanism of action and revealed the importance of the drug as a metal ion chelator. Together, our findings suggest that disulfiram has the potential to be repurposed as an effective antibiotic to treat superficial human skin infections.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9774419 | PMC |
| http://dx.doi.org/10.3390/antibiotics11121752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Harnessing Drug Repurposing to Combat Breast Cancer by Targeting Altered Metabolism and Epithelial-to-Mesenchymal Transition Pathways.
ACS Pharmacol Transl Sci
December 2024
Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati-39, Assam India.
Breast cancer remains one of the most prevalent and challenging cancers to treat due to its complexity and heterogenicity. Cellular processes such as metabolic reprogramming and epithelial-to-mesenchymal transition (EMT) contribute to the complexity of breast cancer by driving uncontrolled cell division, metastasis, and resistance to therapies. Strategically targeting these intricate pathways can effectively impede breast cancer progression, thereby revealing significant potential for therapeutic interventions.
View Article and Find Full Text PDFSafety assessment of disulfiram: real-world adverse event analysis based on FAERS database.
Front Psychiatry
November 2024
Department of Psychiatry, The School of Clinical Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, China.
Article Synopsis
- * A total of 52,159,321 AE reports were reviewed, identifying 508 specifically linked to disulfiram, with major categories including off-label use, psychiatric symptoms, and liver issues, and signaling significant new potential AEs.
- * Despite its benefits as a repurposed medication in fields like oncology and infectious diseases, disulfiram carries risks such as hepatobiliary, psychiatric, and nervous system disorders that require careful monitoring by healthcare providers.
Regaining control over alcohol intake but not abstinence on disulfiram medication, as a harm reduction approach: 2 case reports.
Addict Sci Clin Pract
December 2024
Department of Psychiatry and Psychotherapy, Carl Gustav Carus Faculty of Medicine, Carl Gustav Carus University Hospital Dresden, Dresden University of Technology, Dresden, Germany.
Background: Alcohol use disorder (AUD) poses severe health risks, yet many affected individuals opt out of complete abstinence. Therefore, harm reduction strategies have become more prominent in treatment guidelines for AUD. Our two case reports illustrate how disulfiram, initially intended to enforce abstinence, was repurposed to support reduced drinking.
View Article and Find Full Text PDFAnticancer Effects of New Disulfiram Analogs.
Biol Pharm Bull
November 2024
King Abdullah International Medical Research Center, King Saud Bin Abdelaziz University for Health Sciences.
Disulfiram (DSF), an irreversible aldehyde dehydrogenase 2 (ALDH2) inhibitor, is an U.S. Food and Drug Administration (FDA)-approved drug for the treatment of chronic alcoholism.
View Article and Find Full Text PDFIdentification of two repurposed drugs targeting GSDMD oligomerization interface I to block pyroptosis.
Cell Chem Biol
December 2024
The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Department of Immunology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, School of Basic Medical Sciences, Nanjing Medical University, Nanjing 211166, China. Electronic address:
Article Synopsis
- Gasdermin D (GSDMD) is a key player in inflammatory diseases and cancer, making it a significant target for drug development.
- Current GSDMD inhibitors, like necrosulfonamide, mainly work by modifying specific cysteine residues, which can lead to unwanted side effects.
- This study identifies two safe, repurposed drugs that effectively inhibit GSDMD-mediated pyroptosis, showing potential for enhanced therapeutic effects in treating sepsis and tumors.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!